摘要:
The present invention provides a method of identifying agents that enhance innate immunity in a subject. The invention further provides a method of selectively supressing sepsis by suppressing expression of a proinflammatory gene while maintaining expression of an anti-inflammatory gene. Also provided are methods of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a peptide is described, methods of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response, and compounds and agents identified by the methods of the invention.
摘要:
A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO 23, and SEQ ID NO: 23. A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of an analog of a LL-37 peptide molecule. A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of an exogenous agonist for increasing cellular production and/or cellular activation and/or cellular expression of a LL-37 peptide. Use of one or more of the compositions for treatment of a chronic inflammation condition or an autoimmune disorder.
摘要翻译:用于治疗慢性炎症病症或自身免疫性疾病的组合物,其中所述组合物包含治疗有效量的多肽分子,所述多肽分子包含与选自SEQ ID NO:21的氨基酸序列具有至少80%序列同一性的氨基酸序列 ,SEQ ID NO:22,SEQ ID NO 23和SEQ ID NO:23.用于治疗慢性炎症病症或自身免疫性疾病的组合物,其中所述组合物包含治疗有效量的LL-37肽分子的类似物 。 用于治疗慢性炎症病症或自身免疫性疾病的组合物,其中所述组合物包含治疗有效量的用于增加LL-37肽的细胞产生和/或细胞活化和/或细胞表达的外源激动剂。 一种或多种组合物用于治疗慢性炎症状况或自身免疫性疾病的用途。
摘要:
A composition for preventing or treating inflammatory arthritis wherein the composition comprises an innate defence regulatory peptide named IDR-1002, said peptide comprising an amino acid sequence listing of VQRWLIVWRIRK, and/or a derivative thereof and/or an analog thereof. Use of the IDR-1002 peptide and/or a derivative thereof and/or an analog or a composition comprising the peptide and/or a derivative and/or analog to modulate the expression and/or function of an inflammatory cytokine and/or a matrix metallopeptidase-3 and/or a cell-signalling pathway.